Document:

EX-10.1

 Exhibit 10.1 

SUBSCRIPTION AGREEMENT 
 CytoDyn Inc. 

1111 Main Street, Suite 660 
 Vancouver, Washington 

The undersigned (the “Investor”) hereby confirms its agreement with CytoDyn Inc., a Delaware corporation (the
“Company”), as follows: 
 1. This Subscription Agreement, including the Terms and Conditions For Purchase of Shares
and Warrants attached hereto as Annex I (collectively, (this “Agreement”) is made as of the date set forth below between the Company and the Investor. 

2. The Company has authorized the issuance and sale to certain investors of (i) shares (each a “Share,”
collectively, the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”) and (ii) warrants (each, a “Warrant,” and, collectively, the
“Warrants”), each to purchase one share of Common Stock at an exercise price of $0.75 per share, exercisable for a period of five (5) years from its original date of issuance, to be evidenced by a Common Stock Purchase Warrant
in substantially the form attached hereto as Annex III; with such Shares and Warrants to be issued at an aggregate purchase price of $0.65 (the “Purchase Price”) per fixed combination of one Share and one-half of one Warrant. The Shares and Warrants are immediately separable and will be issued separately. The shares of Common Stock issuable upon exercise of the Warrants are referred to herein as the
“Warrant Shares” and, together with the Shares and the Warrants, are referred to herein as the “Securities”). 

3. The offering and sale of the Securities (the “Offering”) are being made pursuant to (1) an effective
Registration Statement on Form S-3, No. 333-213349 (the “Registration Statement”) filed by the Company with the Securities and Exchange Commission
(the “Commission”) and declared effective on September 9, 2016 (including the base prospectus contained therein (the “Base Prospectus”)), (2) if applicable, certain “free writing prospectuses” (as
that term is defined in Rule 405 under the Securities Act of 1933, as amended (the “Securities Act”)), that have been or will be filed (if required) with the Commission and delivered to the Investor on or prior to the date
hereof, containing certain supplemental information regarding the Securities, the terms of the Offering and the Company (the “Issuer Free Writing Prospectus”), and (3) a prospectus supplement (the “Prospectus
Supplement” and together with the Base Prospectus, the “Prospectus”) containing certain supplemental information regarding the Securities and terms of the Offering that has been or will be filed with the Commission and
delivered to the Investor (or made available to the Investor by the filing by the Company of an electronic version thereof with the Commission). 

4. The Company and the Investor agree that the Investor will purchase from the Company and the Company will issue and sell to the
Investor the Shares and Warrants set forth below for the aggregate purchase price set forth below. The Shares and Warrants shall be purchased pursuant to the Terms and Conditions for Purchase of Shares and Warrants attached

 
hereto as Annex I and incorporated herein by this reference as if fully set forth herein. The Investor acknowledges that the Offering is not being underwritten by
the placement agent (the “Placement Agent”) named in the Prospectus Supplement and that there is no minimum offering amount. 

5. The settlement of the Shares purchased by the Investor shall be effected by crediting the account of the Investor’s prime
broker with the Depository Trust Company (“DTC”) through its Deposit/Withdrawal At Custodian (“DWAC”) delivery system, whereby Investor’s prime broker (as specified by such Investor on Annex II
attached hereto) shall initiate a DWAC transaction on the Closing Date using its DTC participant identification number, and released by Computershare, the Company’s transfer agent (the “Transfer Agent”), at the Company’s
direction. NO LATER THAN ONE (1) BUSINESS DAY AFTER THE EXECUTION OF THIS AGREEMENT BY THE INVESTOR AND THE COMPANY, THE INVESTOR SHALL: 
  

	 	(I)	DIRECT THE BROKER-DEALER AT WHICH THE ACCOUNT OR ACCOUNTS TO BE CREDITED WITH THE SHARES ARE MAINTAINED TO SET UP A DWAC INSTRUCTING THE TRANSFER AGENT TO CREDIT SUCH ACCOUNT OR ACCOUNTS WITH THE SHARES, AND

  

	 	(II)	REMIT BY WIRE TRANSFER THE AMOUNT OF FUNDS EQUAL TO THE AGGREGATE PURCHASE PRICE FOR THE SHARES AND WARRANTS BEING PURCHASED BY THE INVESTOR TO THE FOLLOWING ACCOUNT: 

 

	 	[***]	

 IT IS THE INVESTOR’S RESPONSIBILITY TO (A) MAKE THE NECESSARY WIRE TRANSFER IN
A TIMELY MANNER AND (B) ARRANGE FOR SETTLEMENT BY WAY OF DWAC IN A TIMELY MANNER. IF THE INVESTOR DOES NOT DELIVER THE AGGREGATE PURCHASE PRICE FOR THE SHARES AND WARRANTS OR DOES NOT MAKE PROPER ARRANGEMENTS FOR SETTLEMENT IN A
TIMELY MANNER, THE SHARES AND WARRANTS MAY NOT BE DELIVERED AT CLOSING TO THE INVESTOR OR THE INVESTOR MAY BE EXCLUDED FROM THE CLOSING ALTOGETHER. 

6. The executed Warrants shall be delivered in accordance with the terms thereof. 

7. The Investor represents that, except as set forth below, (a) it has had no position, office or other material relationship
within the past three years with the Company or persons known to it to be affiliates of the Company, (b) it is not a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”) or an Associated Person (as such term is
defined under the FINRA’s NASD Membership and Registration Rules Section 1011) as of the Closing, and (c) neither the Investor nor any group of Investors (as identified in a public filing made with the Commission) of which the
Investor is a part in connection with the Offering, acquired, or obtained the right to acquire, 20% or more of the Common Stock (or securities convertible into or exercisable for Common Stock) or the voting power of the Company on a post-transaction
basis. Exceptions: 
  
  

(If no exceptions, write “none.” If left blank, response will be deemed to be “none.”) 

  
 2 

 8. The Investor represents that it has received (or otherwise had made available to it by
the filing by the Company of an electronic version thereof with the Commission) the Base Prospectus, dated September 9, 2016, which is a part of the Company’s Registration Statement, the documents incorporated by reference therein and
any free writing prospectus (collectively, the “Disclosure Package”), prior to or in connection with the receipt of this Agreement. The Investor acknowledges that, prior to the delivery of this Agreement to the Company,
the Investor will receive certain additional information regarding the Offering, including pricing information (the “Offering Information”). Such information may be provided to the Investor by any means permitted under the
Securities Act, including the Prospectus Supplement, a free writing prospectus and oral communications. 
 9. No offer by the
Investor to buy Shares and Warrants will be accepted and no part of the Purchase Price will be delivered to the Company until the Investor has received the Offering Information and the Company has accepted such offer by countersigning a copy of this
Agreement, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to the Company (or the Placement Agent on behalf of the Company) sending (orally, in writing or by electronic mail) notice of
its acceptance of such offer. An indication of interest will involve no obligation or commitment of any kind until the Investor has been delivered the Offering Information and this Agreement is accepted and countersigned by or on behalf of
the Company. 
 10. The Company acknowledges that the only material, non-public information
relating to the Company or its subsidiaries that the Company, its employees or agents has provided to the Investor in connection with the Offering prior to the date hereof is the existence of the Offering. 

  
 3 

 Number of Shares:
                             

Number of Warrants / Warrants Shares:
                             

Purchase Price Per Combined Share and One-Half of One Warrant: $0.65 

Aggregate Purchase Price:
$                             

Please confirm that the foregoing correctly sets forth the agreement between us by signing in the space provided below for that purpose. 

 

			
	  

INVESTOR

		
	By:	 	  

 
			
	Print Name:	 	  

 
			
	Title:	 	  

 
			
	Address:	 	  

	  

			
	Email:	 	  

 

			
	Agreed and Accepted
	
	CYTODYN INC.
		
	By:	 	  

		 	Name:
		 	Title:

  

			
	Dated as of:	 	  

 ANNEX I 

TERMS AND CONDITIONS FOR PURCHASE OF SHARES AND WARRANTS 

1. Authorization and Sale of the Shares and Warrants. Subject to the terms and conditions of this Agreement, the Company has authorized
the sale of the Shares and Warrants. 
 2. Agreement to Sell and Purchase the Shares and Warrants; Placement Agent. 

2.1 At the Closing (as defined in Section 3.1), the Company will sell to the Investor, and the Investor will
purchase from the Company, upon the terms and conditions set forth herein, the number of Shares and Warrants set forth on the last page of the Agreement to which these Terms and Conditions for Purchase of Shares and Warrants are attached as
Annex I (the “Signature Page”) for the aggregate purchase price therefor set forth on the Signature Page. 

2.2 The Company proposes to enter into substantially this same form of Subscription Agreement with certain other investors (the
“Other Investors”) and expects to complete sales of Shares and Warrants to them. The Investor and the Other Investors are hereinafter sometimes collectively referred to as the “Investors,” and
this Agreement and the Subscription Agreements executed by the Other Investors are hereinafter sometimes collectively referred to as the “Agreements.” 

2.3 Investor acknowledges that the Company has agreed to pay Paulson Investment Company, LLC (the “Placement Agent”)
a fee (the “Placement Fee”) and certain expenses in respect of the sale of Shares and Warrants to the Investor. 

2.4 The Company has entered into a Placement Agent Agreement, dated August 8, 2017, (the “Placement
Agreement”), with the Placement Agent that contains certain representations, warranties, covenants and agreements of the Company that may be relied upon by the Investor, which shall be a third party beneficiary thereof. The
Company confirms that neither it nor any other Person acting on its behalf has provided the Investor or their agents or counsel with any information that constitutes or could reasonably be expected to constitute material, nonpublic information,
except as will be disclosed in the Prospectus and/or in one or more filings pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”) to be made by the Company with the Commission and incorporated by reference
into the Prospectus prior to the consummation of the Offering. The Company understands and confirms that the Investor will rely on the foregoing representations in effecting transactions in securities of the Company. 

3. Closings and Delivery of the Shares and Warrants and Funds. 

3.1 Closing. The completion of the purchase and sale of the Shares and Warrants (the “Closing”) shall
occur at a place and time (the “Closing Date”) to be specified by the Company and the Placement Agent, and of which the Investors will be notified in advance by the Placement Agent, in accordance with Rule 15c6-l promulgated under the Exchange Act. At the Closing, (a) the Company shall cause Computershare, the Company’s transfer agent (the “Transfer Agent”), to deliver to the Investor the
number of Shares set forth on the Signature Page registered in the name of the Investor or, if so indicated on the Investor Questionnaire attached 

  
 I-1 

 
hereto as Annex II, in the name of a nominee designated by the Investor (b) the Company shall cause to be delivered to the Investor one Common
Stock Purchase Warrant, in substantially the form attached hereto as Appendix II, evidencing Warrants to purchase the number of Warrant Shares set forth on the Signature Page and (c) the aggregate purchase price for the Shares and Warrants
being purchased by the Investor will be delivered by or on behalf of the Investor to the Company. 
 3.2 Conditions to the
Obligations of the Parties. 
 (a) Conditions to the Company’s Obligations. The Company’s obligation to
issue and sell the Shares and Warrants to the Investor shall be subject to: (i) the receipt by the Company of the purchase price for the Shares and Warrants being purchased hereunder as set forth on the Signature Page and
(ii) the accuracy of the representations and warranties made by the Investor and the fulfillment of those undertakings of the Investor to be fulfilled prior to the Closing Date. 

(b) Conditions to the Investor’s Obligations. The Investor’s obligation to purchase the Shares and Warrants
will be subject to the accuracy of the representations and warranties made by the Company and the fulfillment of those undertakings of the Company to be fulfilled prior to the Closing Date, including without limitation, those contained in the
Placement Agreement, and to the condition that the Placement Agent shall not have: (a) terminated the Placement Agreement pursuant to the terms thereof or (b) determined that the conditions to the closing in the Placement Agreement
have not been satisfied. The Investor’s obligations are expressly not conditioned on the purchase by any or all of the Other Investors of the Shares and Warrants that they have agreed to purchase from the Company. The Investor understands and
agrees that, in the event that the Placement Agent in its sole discretion determines that the conditions to closing in the Placement Agreement have not been satisfied or if the Placement Agreement may be terminated for any other reason permitted by
such Placement Agreement, then the Placement Agent may, but shall not be obligated to, terminate such Agreement, which shall have the effect of terminating this Subscription Agreement pursuant to Section 14 below. 

3.3 Settlement Procedures. The settlement of the Shares purchased by the Investor shall be effected by crediting the
account of the Investor’s prime broker (as specified by such Investor on Annex II attached hereto) with the Depository Trust Company (“DTC”) through its Deposit/Withdrawal At Custodian
(“DWAC”) delivery system. 
 (a) Delivery of Funds. No later than one
(1) business day after the execution of this Agreement by the Investor and the Company, the Investor shall remit by wire transfer the amount of funds equal to the aggregate purchase price for the Shares and
Warrants being purchased by the Investor to the following account designated by the Company: 
 [***] 

(b) Delivery of Shares. No later than one (1) business day after the execution of this
Agreement by the Investor and the Company, the Investor shall direct the broker-dealer at which the account or accounts to be credited with the Shares being purchased by such Investor are maintained, which
broker/dealer shall be a DTC participant, to set up a DWAC instructing the Transfer Agent to credit such account or accounts with the Shares. Such DWAC 

  
 I-2 

 
instruction shall indicate the settlement date for the deposit of the Shares, which date shall be provided to the Investor by the Placement Agent. Upon the closing of the Offering, the
Company shall direct the Transfer Agent to credit the Investor’s account or accounts with the Shares pursuant to the information contained in the DWAC. 

4. Representations, Warranties and Covenants of the Investor. 

The Investor acknowledges, represents and warrants to, and agrees with, the Company and the Placement Agent that: 

4.1 The Investor (a) is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to,
investments in securities presenting an investment decision like that involved in the purchase of the Shares and Warrants, including investments in securities issued by the Company and investments in comparable companies, (b) has answered
all questions on the Signature Page and the Investor Questionnaire and the answers thereto are true and correct as of the date hereof and will be true and correct as of the Closing Date and (c) in connection with its decision to purchase the
number of Shares and Warrants set forth on the Signature Page, has received and is relying only upon the Disclosure Package and the documents incorporated by reference therein. 

4.2 (a) No action has been or will be taken in any jurisdiction outside the United States by the Company or the Placement Agent that
would permit an offering of the Shares and Warrants, or possession or distribution of offering materials in connection with the issue of the Securities in any jurisdiction outside the United States where action for that purpose is required,
(b) if the Investor is outside the United States, it will comply with all applicable laws and regulations in each foreign jurisdiction in which it purchases, offers, sells or delivers Securities or has in its possession or distributes any
offering material, in all cases at its own expense and (c) the Placement Agent is not authorized to make and has not made any representation, disclosure or use of any information in connection with the issue, placement, purchase and sale of the
Shares and Warrants, except as set forth or incorporated by reference in the Base Prospectus, the Prospectus Supplement or any free writing prospectus. 

4.3 The Investor has full right, power, authority and capacity to enter into this Agreement and to consummate the transactions
contemplated hereby and has taken all necessary action to authorize the execution, delivery and performance of this Agreement, and (b) this Agreement constitutes a valid and binding obligation of the Investor enforceable against the Investor in
accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally and except as
enforceability may be subject to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law) and except as to the enforceability of any rights to indemnification or contribution that may
be violative of the public policy underlying any law, rule or regulation (including any federal or state securities law, rule or regulation). 

4.4 The Investor understands that nothing in this Agreement, the Prospectus, the Disclosure Package or any other materials presented to
the Investor in connection with the purchase and sale of the Shares and Warrants constitutes legal, tax or investment advice. The Investor has consulted such legal, tax and investment advisors and made such investigation as it,

  
 I-3 

 
in its sole discretion, has deemed necessary or appropriate in connection with its purchase of Shares and Warrants. The Investor also understands that there is no established public trading
market for the Warrants being offered in the Offering, and that the Company does not expect such a market to develop. In addition, the Company does not intend to apply for listing of the Warrants on any securities exchange. The Investor understands
that without an active market, the liquidity of the Warrants will be limited. 
 4.5 The Investor will maintain the confidentiality of
all information acquired as a result of the transactions contemplated hereby prior to the public disclosure of that information by the Company in accordance with Section 13 of this Annex. 

4.6 Since the time at which the Placement Agent first contacted such Investor about the Offering, the Investor has not disclosed any
information regarding the Offering to any third parties (other than its legal, accounting and other advisors) and has not engaged in any purchases or sales of the securities of the Company (including, without limitation, any Short Sales (as defined
herein) involving the Company’s securities). The Investor covenants that it will not engage in any purchases or sales of the securities of the Company (including Short Sales) prior to the time that the transactions contemplated by this
Agreement are publicly disclosed. The Investor agrees that it will not use any of the Securities acquired pursuant to this Agreement to cover any short position in the Common Stock if doing so would be in violation of applicable securities laws. For
purposes hereof, “Short Sales” include, without limitation, all “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act, whether or not against the box, and all types of direct and indirect
stock pledges, forward sales contracts, options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h) under the Exchange Act) and similar arrangements (including
on a total return basis), and sales and other transactions through non-U.S. broker dealers or foreign regulated brokers. 

4.7 The Investor is acquiring the Shares and Warrants (including, upon the exercise of the Warrants, the Warrant Shares) solely for such
Investor’s own account for investment purposes only and not with a view to or intent of resale or distribution thereof, in whole or in part. The Investor has no agreement or arrangement, formal or informal, with any person to sell or transfer
all or any part of the Shares, the Warrants, or the Warrant Shares, and the Investor has no plans to enter into any such agreement or arrangement. 

4.8 The Investor has sufficient knowledge and experience in financial and business matters to be capable of evaluating the merits and
risks of an investment in the Securities and is able to bear the economic risks of such investment. 
 4.9 The Investor is unaware of,
is in no way relying on, and did not become aware of the Offering through or as a result of, any form of general solicitation or general advertising including, without limitation, any article, notice, advertisement or other communication published
in any newspaper, magazine or similar media or broadcast over television, radio or the Internet (including, without limitation, internet “blogs,” bulletin boards, discussion groups and social networking sites) in connection with the
Offering and sale of the Securities and is not subscribing for the Securities and did not become aware of the Offering through or as a result of any seminar or meeting to which the Investor was invited by, or any solicitation of a subscription by, a
person not previously known to the Investor in connection with investments in securities generally. 

  
 I-4 

 4.10 The Investor meets the suitability standards set forth in Part B of the Investor
Questionnaire attached hereto as Annex II. 
 4.11 The Investor is aware that the Placement Agent, for the
services it is providing in this Offering will receive, with respect to subscriptions made in this Offering through the Placement Agent, (1) a cash compensation equal to 9% of the gross proceeds received by the Company from such subscribers;
and (2) a warrant to purchase a number of shares equal to 8% of the Shares issued to such subscribers in the Offering. Other than those commissions payable to the Placement Agent as described herein, the Investor has taken no action that would
give rise to any claim by any person for brokerage commissions, finders’ fees or the like relating to this Agreement or the transactions contemplated hereby. 

4.12 The Investor acknowledges that the Placement Agent has acted as a placement agent for the Company in previous offerings of its debt
and equity securities, and the Placement Agent and its registered representatives received, as compensation for those offerings, warrants to purchase shares of the Company’s common stock, which may give Placement Agent as incentive to sell the
Securities to the Investor. 
 4.13 The Investor is aware that a Managing Partner in the Placement Agent’s New York, NY office,
Robert J. Setteducati, entered into a final settlement with the Massachusetts Securities Division in 2001 pursuant to which he agreed, among other things, never to seek to register with the Massachusetts Securities Division in any capacity. The
settlement resolved allegations that Mr. Setteducati failed to adequately supervise employees at a prior broker-dealer. 
 5.
Survival of Representations, Warranties and Agreements; Third Party Beneficiary. Notwithstanding any investigation made by any party to this Agreement or by the Placement Agent, all covenants, agreements, representations and warranties made by
the Company and the Investor herein will survive the execution of this Agreement, the delivery to the Investor of the Shares and Warrants being purchased and the payment therefor. The Placement Agent shall be a third party beneficiary with respect
to the representations, warranties and agreements of the Investor in Section 4 hereof. 
 6. Notices. All
notices, requests, consents and other communications hereunder will be in writing, will be mailed (a) if within the domestic United States by first-class registered or certified airmail, or nationally recognized overnight express courier,
postage prepaid, or by e-mail or (b) if delivered from outside the United States, by International Federal Express or e-mail, and will be deemed given (i) if
delivered by first-class registered or certified mail domestic, three business days after so mailed, (ii) if delivered by nationally recognized overnight carrier, one business day after so mailed, (iii) if delivered by International
Federal Express, two businessdays after so mailed and (iv) if delivered by e-mail, upon electronic confirmation of receipt, and will be delivered and addressed as follows: 

(a) if to the Company, to: 

CytoDyn Inc. 
 1111 Main Street,
Suite 660 
 Vancouver, Washington 

Attention: Michael D. Mulholland, Chief Financial Officer 

Email: mmulholland@cytodyn.com 

  
 I-5 

 
with a copy (which shall not constitute notice) to: 
 Lowenstein Sandler LLP 

1251 Avenue of the Americas 
 New
York, NY 10020 
 Attention: Steven M. Skolnick 

Email: sskolnick@lowenstein.com 

(b) if to the Investor, at its address on the Signature Page hereto, or at such other address or addresses as may have been furnished to the
Company in writing. 
 7. Changes. This Agreement may not be modified or amended except pursuant to an instrument in writing signed by
the Company and the Investor. 
 8. Headings. The headings of the various sections of this Agreement have been inserted for
convenience of reference only and will not be deemed to be part of this Agreement. 
 9. Severability. In case any provision contained
in this Agreement should be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein will not in any way be affected or impaired thereby. 

10. Governing Law. This Agreement will be governed by, and construed in accordance with, the internal laws of the State of New York,
without giving effect to the principles of conflicts of law that would require the application of the laws of any other jurisdiction. 

11. Counterparts. This Agreement may be executed in two or more counterparts, each of which will constitute an original, but all of
which, when taken together, will constitute but one instrument, and will become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. The Company and the Investor acknowledge and agree that
the Company shall deliver its counterpart to the Investor along with the Prospectus Supplement (or the filing by the Company of an electronic version thereof with the Commission). 

12. Confirmation of Sale. The Investor acknowledges and agrees that such Investor’s receipt of the Company’s signed
counterpart to this Agreement, together with the Prospectus Supplement (or the filing by the Company of an electronic version thereof with the Commission), shall constitute written confirmation of the Company’s sale of Shares and Warrants to
such Investor. 
 13. Publicity. The Company and the Investor agree that the Company shall, as promptly as practicable following the
Closing Date, file a current report on Form 8-K with the Securities and Exchange Commission including, but not limited to, a form of this Agreement and forms of Warrant as exhibits thereto. 

  
 I-6 

 14. Termination. In the event that the Placement Agreement is terminated by the Placement
Agent pursuant to the terms thereof, this Agreement shall terminate without any further action on the part of the parties hereto. 

  
 I-7 

 ANNEX II 

INVESTOR QUESTIONNAIRE 

 ANNEX III 

FORM OF COMMON STOCK PURCHASE WARRANTExhibit
10.3

 

Helix
TCS, Inc.

SERIES
B PREFERRED STOCK PURCHASE AGREEMENT

 

This
Series B Preferred Stock Purchase Agreement (this
“Agreement”) is made and entered into as of October 11, 2017, by and among (i) Helix
TCS, Inc., a Delaware corporation (the “Company”), and (ii) RSF4, LLC, a Delaware limited liability
company (the “Purchaser”).

 

Witnesseth

 

Whereas,
the Company has authorized a series of preferred stock in its Series B Certificate of Designation (as defined below) designated
as the “Series B Preferred Stock”, and on May 17, 2017, the Company, the Purchaser and Helix Opportunities, LLC entered
into a series of transactions contemplated by that certain Series B Preferred Stock Purchase Agreement (the “May 2017
SPA”);

 

Whereas,
the Company has authorized the sale and issuance of the value of the Company’s Series B Preferred Stock (the “Series
B Preferred Shares”) which are to be sold at the Closings (as defined in Section 2.1);

 

Whereas,
the Purchaser desires to purchase the Series B Preferred Shares on the terms and conditions set forth herein; and

 

Whereas,
the Company desires to issue and sell the Series B Preferred Shares to the Purchaser on the terms and conditions set forth herein.

 

Agreement

 

Now,
Therefore, in consideration of the foregoing
recitals and the mutual promises, representations, warranties, and covenants hereinafter set forth and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

1.          AGREEMENT
TO SELL AND PURCHASE

 

1.1           Authorization
of Series B Preferred Shares. The Company
has authorized the sale and issuance to the Purchaser of the Series B Preferred Shares. The Series B Preferred Shares have the
rights, preferences, privileges and restrictions set forth in the Charter, including that certain Certificate of Designations,
Preferences and Rights of Series B Preferred Stock in the form attached to the May 2017 SPA (the “Series B Certificate
of Designation”).

 

1.2           Sale
and Purchase. The Company hereby agrees to issue and sell to the Purchaser and, subject to and in reliance upon the
representations, warranties, covenants, terms and conditions hereof, at the Closings, the Purchaser agrees to purchase, from the
Company, 462,195 Series B Preferred Shares (the “Purchased Series B Shares”) in exchange for an aggregate
cash payment equal to $150,000.00 (i.e., a per share price equal to $0.3245 (the “Per Share Purchase Price”)).

 

    1

     

    

 

2.          CLOSINGS,
DELIVERY AND PAYMENT

 

2.1           Closings.

 

(a)          Closings.
The sale and purchase of the Series B Preferred Shares shall occur 50% on October 11, 2017 and 50% on October 18, 2017 (the
“Closings”).

 

(b)          Rights
to Purchase Pursuant to Subsequent Closing under May 2017 SPA.
This purchase of Series B Preferred Shares shall be considered a Subsequent Closing as that term is defined in the Series B Preferred
Stock Purchase Agreement consummated by the Parties on May 17, 2017 (the May Agreement”) and shall be counted
against the Maximum Amount as that term is also defined in the May Agreement.

 

2.2           Use
of Proceeds. The Company covenants and agrees
to use the proceeds from the sale of the Series B Preferred Shares for working capital purposes.

 

2.3           Payment.
The Purchaser shall pay for the Series B Preferred Shares by wire transfer in accordance with instructions provided by the Company
in an amount equal to the Per Share Purchase Price multiplied by the number of the Series B Preferred Shares purchased.

 

2.4           Delivery.
At the Closings, subject to the terms and conditions
hereof and upon payment of the purchase price therefor, the Company will deliver to the Purchaser a certificate, duly signed by
an authorized agent of the Company, representing the Purchased Series B Shares.

 

3.          REPRESENTATIONS
AND WARRANTIES OF THE COMPANY

 

Except
as set forth on a Schedule of Exceptions attached hereto (the “Schedule of Exceptions”), the Company,
on behalf of itself and each member of the Company Group, hereby represents and warrants to the Purchaser as of the date of this
Agreement as set forth below. For purposes of this Section 3, the phrase “to the Company’s knowledge” means
the actual knowledge of the executive officers of the Company.

 

3.1           Organization,
Good Standing and Qualification. The Company is a corporation duly incorporated,
validly existing and in good standing under the laws of the State of Delaware. The Company has all requisite corporate power and
authority and any government consents and approvals to (i) own and operate its properties and assets, (ii) execute and deliver
this Agreement, (iii) issue and sell the Series B Preferred Shares, (iv) carry out the provisions of this Agreement, the Series
B Financing Agreements (as such term is defined in the May 2017 SPA) and the Charter and (v) carry on its business as presently
conducted. The Company is duly qualified and is authorized to do business and is in good standing as a foreign corporation in
all jurisdictions in which the nature of its activities and of its properties (both owned and leased) makes such qualification
necessary, except for those jurisdictions in which failure to do so would not have a material adverse effect on the assets, liabilities,
financial condition, prospects or operations of the Company. For the purposes of this Agreement, the Company’s original
Certificate of Incorporation filed with the Secretary of the State of Delaware on March 13, 2014 (the “Original Certificate”),
as (i) amended on May 6, 2014 (in order to correct a misspelling), (ii) further amended on May 6, 2014, (iii) amended on October
14, 2015, (iv) amended on December 28, 2015 pursuant to an amendment which included the Certificate of Designation of Rights and
Privileges of Class A Preferred Convertible Super Majority Voting Stock (the “Original Series A Certificate of Designation”),
and (v) further amended on May 15, 2017 pursuant to an amendment which included the Series B Certificate of Designation (the amendments
described in the foregoing clauses (i)-(v), collectively, the “Charter Amendments”, and the Original
Certificate and the Amendments are together, collectively referred to herein as the “Charter”.

 

    2

     

    

 

3.2           Capitalization;
Voting Rights.

 

(a)          The
authorized capital stock of the Company, immediately prior to the Closings consists of (i) 200,000,000 shares of common stock,
par value $0.001 per share, 28,644,522 shares of which are issued and outstanding (the “Common Stock”),
and (ii) 20,000,000 shares of Preferred Stock, par value $0.001 per share, (A) 1,000,000 of which are designated “Series A
Preferred Stock” in the Charter, as may be amended from time to time in accordance with this Agreement (the “Series
A Preferred Stock”), all of which are issued and outstanding immediately prior to the Closings; and (B) 13,000,000
of which are designated “Series B Preferred Stock”, 9,830,035 of which are issued and outstanding immediately prior
to the Closings. Attached as Schedule 3.2(a) sets forth the capitalization of the Company immediately prior to the
Closings.

 

(b)          Other
than (i) rights to purchase additional shares of the Common Stock vested in those persons and entities and determined as described
in Schedule 3.2(b) attached hereto, and (iii) except as may otherwise be granted pursuant to this Agreement, the
May 2017 SPA and any agreement related thereto (collectively the “Series B Financing Agreements”) , there are no outstanding
options, warrants, rights (including conversion or preemptive rights and rights of first refusal), proxy or stockholder agreements,
or agreements of any kind, including agreements contingent on the occurrence of possible future events, for the purchase or acquisition
from the Company of any of its securities.

 

(c)          The
rights, preferences, privileges and restrictions applicable to the Series B Preferred Shares are as stated in the Series B Certificate
of Designation. When issued in compliance with the provisions of this Agreement and the Charter, the Series B Preferred Shares
will be validly issued, fully paid and nonassessable, and will be free of any liens or encumbrances other than liens and encumbrances
created by Purchaser; provided, however, that the Series B Preferred Shares may be subject to restrictions on transfer under the
Series B Financing Agreements, and state and/or federal securities laws as set forth herein or as otherwise required by such laws
at the time a transfer is proposed.

 

(d)          Except
as set forth in Schedule 3.2(d) attached hereto, no stock plan, stock purchase, stock option or other agreement
or understanding between the Company and any holder of any equity securities or rights to purchase equity securities provides
for mandatory acceleration or other changes in the vesting provisions or other terms of such agreement or understanding as the
result of (i) termination of employment (whether actual or constructive); (ii) any merger, consolidated sale of stock or assets,
change in control or any other transaction(s) by the Company; (iii) the transactions contemplated hereby or (iv) the occurrence
of any other event or combination of events.

 

    3

     

    

 

3.3           Authorization;
Binding Obligations.

 

(a)          All
corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization of this
Agreement, the performance of all obligations of the Company hereunder at the Closings, the authorization, sale, issuance and
delivery of the Series B Preferred Shares pursuant hereto.

 

(b)          This
Agreement, when executed and delivered by the Company, will (assuming the due authorization, execution and delivery hereof by
the Purchaser and other parties thereto) be legal, valid and binding obligations of the Company enforceable in accordance with
their respective terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws
of general application affecting enforcement of creditors’ rights, (b) general principles of equity that restrict the
availability of equitable remedies, and (c) to the extent that the enforceability of the indemnification provisions in the
Series B Financing Agreements may be limited by applicable laws.

 

3.4           No
Insolvency. No insolvency proceeding of any character, including, without limitation,
bankruptcy, receivership, reorganization, composition or arrangement with creditors, voluntary or involuntary, affecting the Company
or any of its assets or properties, is pending or, to the Company's knowledge, threatened. Neither the Company, nor any of its
subsidiaries (collectively, with the Company, the “Company Group”), has taken any action in contemplation
of, or that would constitute the basis for, the institution of any such insolvency proceedings.

 

3.5           Litigation.
Other than the two lawsuits by three former employees previously disclosed by the Company, there is no (a) action,
suit, proceeding or investigation pending or, to the Company’s knowledge, currently threatened against any member of the
Company Group before or by any Federal, state, municipal or other governmental department, commission, board, bureau, agency or
instrumentality, domestic or foreign, (b) arbitration proceeding relating to any member of the Company Group pending or (c) governmental
inquiry pending or, to the Company’s knowledge, currently threatened against any member of the Company Group (including
without limitation any inquiry as to the qualification of the Company to hold or receive any license or permit), nor is the Company
aware that there is any basis for any of the foregoing.

 

3.6           Tax
Returns and Payments. The Company has timely filed all tax returns and
reports as required by federal, state and local law. These returns and reports are true and correct in all material respects.
The Company has paid all taxes and other assessments due, except those contested by it in good faith. The provision for taxes
of the Company as shown in the Financial Statements is adequate for taxes due or accrued as of the date thereof. The Company has
elected pursuant to the Internal Revenue Code of 1986, as amended (the “Code”), to be treated as a corporation.
During the past three (3) years, the Company has not had any tax deficiency proposed or assessed against it and has not executed
any waiver of any statute of limitations on the assessment or collection of any tax or governmental charge. During the past three
(3) years, none of the Company’s federal income tax returns and none of its state income or franchise tax or sales or use
tax returns has ever been audited by governmental authorities. The Company has withheld or collected from each payment made to
each of its employees the amount of all taxes, including, but not limited to, federal income taxes, Federal Insurance Contribution
Act taxes and Federal Unemployment Tax Act taxes required to be withheld or collected therefrom, and has paid the same to the
proper tax receiving officers or authorized depositaries.

 

    4

     

    

 

3.7           Disclosure.
The Company has made available to the Purchaser all the information reasonably available to the Company and its subsidiaries
that the Purchaser have requested for deciding whether to acquire the Purchased Series B Shares. No representation or warranty
of the Company contained in this Agreement, as qualified by the Schedule of Exceptions, and no certificate or other information
furnished or to be furnished to Purchaser at the Closings contains any untrue statement of a material fact or omits to state a
material fact necessary in order to make the statements contained herein or therein not misleading in light of the circumstances
under which they were made.

 

4.          REPRESENTATIONS
AND WARRANTIES OF THE PURCHASER.

 

Purchaser
hereby represents and warrants to the Company as follows (such representations and warranties do not lessen or obviate the representations
and warranties of the Company set forth in this Agreement):

 

4.1           Requisite
Power and Authority. Such Purchaser has all necessary power and authority
under all applicable provisions of law to execute and deliver this Agreement and to carry out its provisions. All action on such
Purchaser’s part required for the lawful execution and delivery of this Agreement have been or will be effectively taken
prior to the Closings. Upon its execution and delivery, this Agreement will be valid and binding obligations of such Purchaser,
enforceable in accordance with its terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium
or other laws of general application affecting enforcement of creditors’ rights, and (b) as limited by general principles
of equity that restrict the availability of equitable remedies.

 

4.2           Investment
Representations. Such Purchaser understands that none of the Purchased
Series B Shares have been registered under the Securities Act. Such Purchaser also understands that the Series B Preferred Shares
are being offered and sold pursuant to an exemption from registration contained in the Securities Act based in part upon such
Purchaser’s representations contained in the Agreement. Such Purchaser hereby represents and warrants as follows:

 

(a)          Purchaser
Bears Economic Risk. Such Purchaser has substantial experience in evaluating and investing in private placement transactions
of securities in companies similar to the Company so that it is capable of evaluating the merits and risks of its investment in
the Company and has the capacity to protect its own interests. Such Purchaser must bear the economic risk of this investment indefinitely
unless the Purchased Series B Shares are registered pursuant to the Securities Act, or an exemption from registration is available.
Such Purchaser understands that the Company has no present intention of registering the Purchased Series B Shares or any shares
of the Common Stock. Such Purchaser also understands that there is no assurance that any exemption from registration under the
Securities Act will be available and that, even if available, such exemption may not allow such Purchaser to transfer all or any
portion of the Purchased Series B Shares under the circumstances, in the amounts or at the times that such Purchaser might propose
or desire.

 

    5

     

    

 

(b)          Acquisition
for Own Account. Such Purchaser is acquiring the Purchased Series B Shares for such Purchaser’s own account for investment
only, and not with a view to distribution, assignment or resale of the Purchased Series B Shares to others or to fractionalization
of the Purchased Series B Shares in whole or in part, in each case, in violation of the Securities Act.

 

(c)          Purchaser
Can Protect Its Interest. Such Purchaser represents that by reason of its, or of its management’s, business or financial
experience, such Purchaser has the capacity to protect its own interests in connection with the transactions contemplated in this
Agreement. Further, such Purchaser is aware of no publication of any advertisement in connection with the transactions contemplated
in the Agreement.

 

(d)          Accredited
Investor. Such Purchaser represents and warrants that it is an “accredited investor” within the meaning of Rule
501 of Regulation D, as promulgated under the Securities Act. Purchaser represents and warrants that, to the best of such Purchaser’s
knowledge (after due inquiry), each equity owner of such Purchaser is also an “accredited investor” within the meaning
of Regulation D, as promulgated under the Securities Act.

 

(e)          Rule
144. Such Purchaser acknowledges and agrees that in addition to any requirements under state securities laws, the Series B
Preferred Shares are “restricted securities” as defined in Rule 144 promulgated under the Securities Act as in effect
from time to time (“Rule 144”) and must be held indefinitely unless they are subsequently registered
under the Securities Act or an exemption from such registration is available. Such Purchaser has been advised or is aware of the
provisions of Rule 144, which permits limited resale of shares purchased in a private placement subject to the satisfaction of
certain conditions, including, among other things, the availability of certain current public information about the Company, the
resale occurring following the required holding period under Rule 144, and the number of shares being sold during any three-month
period not exceeding specified limitations. Such Purchaser has been further advised that the Company has no present intention
of satisfying the current public information requirements of Rule 144, and as a result such Purchaser will be able to rely on
Rule 144 only under the limited circumstances described in that rule.

 

(f)          Residence.
Purchaser is a resident of the state of New York.

 

(g)          Foreign
Investors. If such Purchaser is not a United States person (as defined by Section 7701(a)(30) of the Code), such Purchaser
hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any
invitation to subscribe for the Purchased Series B Shares or any use of this Agreement, including (i) the legal requirements within
its jurisdiction for the purchase of the Purchased Series B Shares, (ii) any foreign exchange restrictions applicable to such
purchase, (iii) any government or other consents that may need to be obtained, and (iv) the income tax and other tax consequences,
if any, that may be relevant to the purchase, holding, redemption, sale or transfer of the Purchased Series B Shares. Such Purchaser’s
subscription and payment for and continued beneficial ownership of the Purchased Series B Shares will not violate any applicable
securities or other laws of such Purchaser’s jurisdiction.

 

    6

     

    

 

(h)          No
General Solicitation. To the knowledge of such Purchaser, the Series B Preferred Shares have not been offered to such Purchaser
by any form of general solicitation or general advertising, including, without limitation, (A) any advertisement, article, notice
or other communication published in any newspaper, magazine or similar media, or broadcast over television or radio, or (B) any
seminar or meeting whose attendees (including the Purchaser) have been invited by any general solicitation or general advertising.

 

4.3           Transfer
Restrictions. Such Purchaser acknowledges and agrees that the Purchased
Series B Shares are subject to restrictions on transfer as set forth in the Series B Financing Agreements.

 

4.4           Not
a Bad Actor. Neither Purchaser nor any of its affiliates that could stand as beneficial owner of the Securities purchased
hereunder, is subject to any of the “Bad Actor” disqualifications described in Securities Act Rule 506(d)(1) subsections
(i) through (viii).

 

5.          MISCELLANEOUS.

 

5.1           Governing
Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by and construed in accordance
with the General Corporation Law of the State of Delaware, without regard to its principles of conflicts of laws. Each of the
parties hereto irrevocably submits to the exclusive jurisdiction of the courts of the State of Delaware located in Wilmington,
Delaware and the United States District Court for the District of Delaware for the purpose of any suit, action, proceeding or
judgment relating to or arising out of this Agreement and the transactions contemplated hereby.  Service of process in connection
with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified
for the giving of notices under this Agreement.  Each of the parties hereto irrevocably consents to the jurisdiction of any
such court in any such suit, action or proceeding and to the laying of venue in such court.  Each party hereto irrevocably
waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives
any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. 
EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS
THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.

 

5.2           Successors
and Assigns. Except as otherwise expressly provided herein, the provisions
hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the
parties hereto and shall inure to the benefit of and be enforceable by each person who shall be a holder of the Series B Preferred
Shares from time to time.

 

5.3           Entire
Agreement. This Agreement together with the Series Financing Agreements,
subject to the waivers provided herein, the exhibits and schedules hereto and thereto, and the other documents delivered pursuant
hereto and thereto constitute the full and entire understanding and agreement between the parties with regard to the subjects
hereof and thereof and no party shall be liable or bound to any other in any manner by any representations, warranties, covenants
and agreements except as specifically set forth herein and therein.

 

    7

     

    

 

5.4           Severability.
In case any provision of the Agreement shall be invalid, illegal or unenforceable, the validity, legality and enforceability
of the remaining provisions shall not in any way be affected or impaired thereby.

 

5.5           Amendment
and Waiver.

 

(a)          This
Agreement may be amended or modified only upon the written consent of the Company and holders of at least a majority of the Series
B Preferred Shares then outstanding (treated as if converted into which the Series B Preferred Shares have been converted that
have not been sold to the public). Any such amendment or modification effected in accordance with this Section 5.5(a) shall be
binding on all parties hereto, even if they do not execute such consent.

 

(b)          Subject
to Section 5.5(c) below, any party hereto may waive compliance with any agreements, covenants or conditions for the benefit of
such party contained herein. Any agreement on the part of a party hereto to any such waiver shall be valid only if set forth in
an instrument in writing signed on behalf of such party.

 

(c)          The
obligations of the Company and the rights of the holders of the Series B Preferred Shares under the Agreement may be waived (either
generally or in a particular instance and either retroactively or prospectively) only with the written consent of the holders
of at least a majority of the Series B Preferred Shares then outstanding (treated as if converted into which the Series B Preferred
Shares have been converted that have not been sold to the public). Any such waiver effected in accordance with this Section 5.5(c)
shall be binding on all parties hereto, even if they do not execute such consent.

 

(d)          The
Purchaser expressly waives and acknowledges the satisfaction of any and all terms and conditions contained in the Series B Financing
Agreements as it relates to the Closings under this Agreement, including the terms and conditions set forth in Section 2.1 of
the May 2017 SPA; provided that, for the avoidance of doubt, such waiver does not limit or impair Purchaser’s rights under
Section 2.1(b) in a subsequent closing following the Closings.

 

5.6           Delays
or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party, upon any breach, default
or noncompliance by another party under this Agreement, or the Charter, shall impair any such right, power or remedy, nor shall
it be construed to be a waiver of any such breach, default or noncompliance, or any acquiescence therein, or of or in any similar
breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent or approval of any
kind or character on Purchaser’s part of any breach, default or noncompliance under this Agreement, or under the Charter
or any waiver on such party’s part of any provisions or conditions of the Agreement or the Charter must be in writing and
shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement, the Charter,
by law, or otherwise afforded to any party, shall be cumulative and not alternative.

 

    8

     

    

 

5.7           Notices.
All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal
delivery to the party to be notified, (b) when sent by confirmed telex or facsimile if sent during normal business hours
of the recipient, if not, then on the next business day, (c) five (5) days after having been sent by registered or certified
mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight
courier, specifying next day delivery, with written verification of receipt.

 

5.8           Expenses.
The Company and the Purchaser shall each pay their own expenses in connection with the transactions contemplated by this
Agreement.

 

5.9           Attorneys’
Fees. In the event that any suit or action is instituted to enforce any
provision in this Agreement, the prevailing party in such dispute shall be entitled to recover from the losing party all fees,
costs and expenses of enforcing any right of such prevailing party under or with respect to this Agreement, including without
limitation, such reasonable fees and expenses of attorneys and accountants, which shall include, without limitation, all fees,
costs and expenses of appeals.

 

5.10         Titles
and Subtitles. The titles of the sections and subsections of the Agreement
are for convenience of reference only and are not to be considered in construing this Agreement.

 

5.11         Pronouns.
All pronouns contained herein, and any variations thereof, shall be deemed to refer to the masculine, feminine or neutral,
singular or plural, as to the identity of the parties hereto may require.

 

5.12         Counterparts.
This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall
constitute one instrument. This Agreement may be executed by facsimile signatures or via .pdf signature.

 

Signatures
on the Following Page

 

    9

     

    

 

This
Series B Preferred Stock Purchase Agreement is hereby executed as of the
date first above written.

 

	The
    Company:	 
	 	 
	Helix
    TCS, Inc.	 
	 	 
	By:	 	 
	Name:	Zachary L. Venegas	 
	Title:	Chief Executive Officer	
	 	 
	The
    Purchaser:	 
	 	 
	RSF4,
    LLC	 
	 	 
	By: Rose
    Capital Fund I GP, LLC, its Manager	 
	 	 
	By:	 	 
	 	Name: Andrew Schweibold	 
	 	Title: Principal	
	 	 
	By:	 	 
	 	Name: Jonathan Rosenthal	 
	 	Title: Principal	

 

Helix
TCS, Inc. Series B Preferred Stock Purchase Agreement

Signature
Page

  

     

     

    

 

Schedule
3.2(a)

Capitalization

 

See
attached Capitalization Table

  

Schedule
3.2(b)

Purchase
Rights

 

	Paul
    Hodges	1,920,000
    warrants @$0.16 per share
	Red Diamond, LLC	25,000 cashless
    warrants @ $1.00 per share
	Red Diamond, LLC	150,000 cashless
    warrants @ $1.00 per share
	Andrew Feldschreiber	231,098 warrants
    @ $0.3245 per share
	Evan Schwartzberg	134,036 warrants
    @ $0.3245 per share
	Mathew Van Alstyne	97,061 warrants
    @ $0.3245 per share
	Former Security
    Grade Shareholders	414,854 warrants
    @ $0.001 per share

 

The
convertible notes described in Schedule 3.2(a) above are incorporated herein by reference

  

Schedule
3.2(d)

Acceleration
of Rights

 

Red
Diamond Warrants

Former
Security Grade Shareholders Warrants

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]